Medicenna announces upcoming presentations at the association

Toronto and Houston, October. May 5, 2022 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company, today announced the acceptance of cancer Two abstracts from the Society for Immunotherapy (SITC) 37 poster presentationth The annual meeting will be held virtually and in-person from November 8-12, 2022 at the Boston Convention and Exhibition Center in Boston, Massachusetts.

SITC will publish both summaries on November 7, 2022 at 8:00AM ET. The abstract and other details of the corresponding poster presentation are shown below.

title: Pharmacokinetic and pharmacodynamic characterization of first-in-human studies with MDNA11, an engineered long-acting “beta-only” IL2 agonist
Abstract number: 743
Poster presentation date and time: November 10, 2022, 9:00am-9:00pm ET
Poster session location: Boston Convention and Exhibition Center Hall C

title: Interim single-agent safety and antitumor activity in the dose-escalation phase of the long-acting beta-only IL-2 agonist MDNA11
Abstract number: 744
Poster presentation date and time: November 11, 2022, 9:00am-8:30pm ET
Poster session location: Boston Convention and Exhibition Center Hall C

About Medison
Medicenna is a clinical-stage immunotherapy company focused on the development of novel, highly selective IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Medicenna’s long-acting IL-2 Superkine MDNA11 is a next-generation IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Medicenna’s early BiSKITs™ program, (pairfunctional smallexcellentKexist A generationMonoTontreats) is designed to enhance the ability of Superkines to treat immune “cold” tumors. Medicenna’s IL-4 Empowered Superkine MDNA55 has been studied in five clinical trials, including a Phase 2b trial in recurrent GBM, the most common and consistently lethal form of brain cancer. MDNA55 has been granted Fast Track and Orphan Drug status by the FDA and FDA/EMA, respectively.


Source link